Positive top line results from confirmatory efficacy study for proposed biosimilar to xolair® (omalizumab)

Reykjavik, iceland and piscataway, n.j. and london, june 25, 2025 (globe newswire) -- alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, kashiv biosciences llc (“kashiv”), a fully integrated biopharmaceutical company headquartered in new jersey, us, and advanz pharma holdco limited (“advanz pharma”), a uk-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced positive topline results from a confirmatory efficacy study comparing avt23 (adl-018), a proposed biosimilar to xolair® (omalizumab), with the reference biologic.
ALVO Ratings Summary
ALVO Quant Ranking